Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2019
Reporting Period: Second quarter ended June 30, 2019
Context: This filing announces the issuance of a press release regarding financial results for the second quarter of 2019. The detailed financial data is contained in Exhibit 99.1 (Press Release) and is not explicitly detailed within the body of this 8-K text.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release furnished as Exhibit 99.1, which is incorporated by reference but not reproduced in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
- Conference Call: Management scheduled a conference call for August 7, 2019, at 9:00 a.m. Eastern Time to present business and financial results.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties.
- Risk Factors: The document directs readers to Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, for a detailed discussion of risks.
- Legal Disclaimer: Information in Item 2.02 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2019 revenue, net loss, and cash position figures.
- Access the archived webcast of the August 7, 2019, conference call for management commentary on the results.
- Consult the 2018 Form 10-K (filed March 1, 2019) for the full list of risk factors referenced in this filing.
- Verify the company's status as an emerging growth company (indicated as not applicable in this filing).